07/01 - 09/01
Parc 55 Hotel 55 Cyril Magnin Street, San Francisco, CA 94102
Stand Alliance Davidson Room Level 4 Contact us for a meeting
We will be present at this event together with our partners of the PROVEO Alliance to discuss actual and new development and manufacturing opportunities
Cerbios-Pharma SA (from now on “Cerbios”) board of directors has approved the detailed design and budget for the installation in its High Potency Active Ingredients (HPAIs) dedicated building of a new production line able to accommodate larger volumes and batch size.
Cerbios is active in the HPAI arena since 1993 with an established expertise on handling Category 4 SafeBridge (OEL<10 ng/m3) Drug Substances in four different lines: 2 non cGMP ; 2 cGMP.
The P5 building for larger scale cGMP production of HPAIs was originally conceived with empty spaces available for installing an additional production line.
The new production line (..)
Cerbios has been awarded second place at the bi-annual Swiss Venture Club Prix.
“This is an important recognition for Cerbios, the founders that created it in the late 70’s, the management and all employees that made this possible” confirms Gabriel Haering, Cerbios’ CEO.
“Being one of the six finalists chosen among 50 companies representing different industrial branches in Ticino was already a great achievement. Reaching the second place among the six finalist is splendid!”
The main criteria for the choice of finalists and winners were the following:
This award is not only a recognition for Cerbios’ strategy and approach but also a commitment towards the future in order to maintain the high standard achieved.